Pharming reacquires RUCONEST®-licensed territories from Sobi
Pharming Group N.V. (Euronext Amsterdam: PHARM) today announced it has entered into a definitive agreement with Swedish Orphan Biovitrum AB (publ) (“Sobi”) to reacquire the commercial rights to Pharming’s product, RUCONEST®, in all remaining territories, which includes all remaining EU markets. Under the agreement, the license is being terminated with effect from 1 January 2020 in all 36 countries with a smooth handover planned in the countries where Sobi has sales activities. Pharming will pay Sobi €7.5 million in two tranches.
The transaction will enable us to drive further growth of RUCONEST® and will be accretive to earnings immediately. In addition, we will expand our existing commercial infrastructure in Europe to support the expected launch of future new products- Sijmen de Vries - CEO